Provenge – Sipuleucel-T may have added benefit in prostate cancer

Sipuleucel-T in prostate cancer: Indication of added benefit – Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.

Chronic fatigue syndrome is not psychological disease

Scientists discover robust evidence that chronic fatigue syndrome is a biological illness – Immune signatures in blood point to distinct disease stages, open door to better diagnosis and treatment – Researchers identified distinct immune changes in patients diagnosed with chronic fatigue syndrome, known medically as myalgic encephalomyelitis (ME/CFS) or systemic exertion intolerance disease.

Health Newstrack